<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662017000200226</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Inhibición de PCSK9: una nueva alternativa para reducir el colesterol y prevenir la enfermedad cardiovascular aterosclerosa]]></article-title>
<article-title xml:lang="en"><![CDATA[Inhibition of PCSK9: a new alternative for cholesterol reduction and prevention of atherosclerotic cardiovascular disease]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montaño-Sosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aragón-Torres]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Girón-Arellano]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Reséndiz-Meléndez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ahumada-Ayala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Ángeles Pedregal Departamento de Medicina Interna y Endocrinología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<volume>33</volume>
<numero>2</numero>
<fpage>226</fpage>
<lpage>237</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662017000200226&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662017000200226&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662017000200226&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La enfermedad cardiovascular aterosclerosa ocupa el primer lugar mundial en morbilidad y mortalidad. El principal factor de riesgo de enfermedad es el colesterol unido a lipoproteínas de baja densidad (C-LDL). El tratamiento farmacológico de elección para reducir el C-LDL son las estatinas; sin embargo, han sido insuficientes para eliminar el riesgo cardiovascular, especialmente en pacientes con formas primarias de hipercolesterolemia relacionadas con mutaciones genéticas, o intolerantes a estatinas. Es de gran importancia el desarrollo de nuevos fármacos para abatir el riesgo que persiste a pesar de la administración de estatinas. La proconvertasa subtilisina-kexina 9 (PCSK9) es un regulador primordial de la cantidad de receptores de LDL, ya que su función es dirigir dichos receptores a su destrucción lisosomal. El advenimiento de anticuerpos monoclonales para bloquear la PCSK9 ha permitido mejorar la cantidad y eficiencia de los receptores de LDL, de esto resulta la disminución notable del colesterol circulante. Hasta el momento, la eficacia e inocuidad de estos anticuerpos resultan aceptables, y los datos preliminares en cuanto a su efecto en la reducción de la morbilidad y mortalidad cardiovasculares son alentadores.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Atherosclerotic cardiovascular disease represents the leading cause of morbidity and mortality in most countries. The main risk factor for developing this disease is low density lipoprotein cholesterol (LDL-C). The pharmacological treatment of choice for reducing LDL-C is statins; however, in spite of the widespread use of statins, these drugs have been insufficient to eliminate cardiovascular risk. This residual risk is most relevant in patients with primary forms of hypercholes-terolemia associated with genetic mutations, or in those who are intolerant to statins. The development of new drugs to reduce residual cardiovascular risk is of vital importance. Proprotein convertase subtilisin-kexin 9 (PCSK9) is an important regulator of the amount of LDL receptors since its function is to direct these receptors to their lysosomal destruction. The development of monoclonal antibodies to block extracellular PCSK9 has allowed us to improve the quantity and efficiency of LDL receptors, resulting in a significant decrease in plasma cholesterol. Efficacy and safety of these antibodies is currently considered acceptable and preliminary data are encouraging but still insufficient to assess the favorable impact of these antibodies in reducing cardiovascular morbidity and mortality.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[PCSK9]]></kwd>
<kwd lng="es"><![CDATA[colesterol]]></kwd>
<kwd lng="es"><![CDATA[C-LDL]]></kwd>
<kwd lng="es"><![CDATA[riesgo cardiovascular]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos monoclonales]]></kwd>
<kwd lng="es"><![CDATA[estatinas]]></kwd>
<kwd lng="es"><![CDATA[evolocumab]]></kwd>
<kwd lng="es"><![CDATA[alirocumab]]></kwd>
<kwd lng="es"><![CDATA[inclisirán]]></kwd>
<kwd lng="en"><![CDATA[PCSK9]]></kwd>
<kwd lng="en"><![CDATA[cholesterol]]></kwd>
<kwd lng="en"><![CDATA[LDL-C]]></kwd>
<kwd lng="en"><![CDATA[cardiovascular risk]]></kwd>
<kwd lng="en"><![CDATA[monoclonal antibodies]]></kwd>
<kwd lng="en"><![CDATA[statins]]></kwd>
<kwd lng="en"><![CDATA[evolocumab]]></kwd>
<kwd lng="en"><![CDATA[alirocumab]]></kwd>
<kwd lng="en"><![CDATA[inclisiran]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stock]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Ginsberg]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PCSK9 inhibitors and cardiovascular disease heralding a new therapeutic era]]></article-title>
<collab>&ampPCSK9 Forum</collab>
<source><![CDATA[Curr Opin Lipidol USA]]></source>
<year>2015</year>
<volume>26</volume>
<page-range>511-20</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A century of cholesterol and coronaries From plaques to genes to statins]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<source><![CDATA[Cell USA]]></source>
<year>2015</year>
<volume>161</volume>
<page-range>161-72</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Low-density lipoprotein receptor (LDLR) Family orchestrates cholesterol homeostasis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Go]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Yale J Biol Med USA]]></source>
<year>2012</year>
<volume>85</volume>
<page-range>19-28</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of PCSK9 inhibition on coronary atheroma progression Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puri]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nissen]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Somaratne]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kastelein]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ballantyne]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<source><![CDATA[Am Heart J]]></source>
<year>2016</year>
<volume>176</volume>
<page-range>83-92</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maningat]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How do we improve patient compliance and adherence to long-term statin therapy]]></article-title>
<collab>&ampBreslow JL</collab>
<source><![CDATA[Curr Atheroscler Rep]]></source>
<year>2013</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism why have they failed in lowering coronary heart disease risk?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaefer]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Lipidol]]></source>
<year>2013</year>
<volume>24</volume>
<page-range>259-64</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treating to new targets investigators HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barter]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gotto]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[LaRosa]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Maroni]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl Med USA]]></source>
<year>2007</year>
<volume>357</volume>
<page-range>1301-10</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia Results of a 24 week, double-blind, randomized Phase 3 trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roth]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Taskinen]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Ginsberg]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
<name>
<surname><![CDATA[Kastelein]]></surname>
<given-names><![CDATA[JJP]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Cardiol Heart Vasc]]></source>
<year>2014</year>
<volume>176</volume>
<page-range>55-61</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy]]></article-title>
<collab>InvestigatorsAH</collab>
<source><![CDATA[N Engl J Med USA]]></source>
<year>2011</year>
<volume>365</volume>
<page-range>2255-67</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Use of lipid-lowering edications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karalis]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Victor]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ahedor]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Cholesterol USA]]></source>
<year>2012</year>
<volume>2012</volume>
<page-range>861-924</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease meta-analysis of individual data from 27 randomised trials]]></article-title>
<collab>Cholesterol Treatment Trialists' Collaborators</collab>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>380</volume>
<page-range>581-90</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical aspects of PCSK9]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cariou]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Le May]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Costet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Atherosclerosis]]></source>
<year>2011</year>
<volume>216</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>258-65</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sjouke]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Defesche]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[de Randamie]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Wiegman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Atherosclerosis]]></source>
<year>2016</year>
<volume>251</volume>
<page-range>263-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PCSK9 A key modulator of cardiovascular health]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seidah]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Awan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Chrétien]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mbikay]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Circ Res]]></source>
<year>2014</year>
<volume>6</volume>
<page-range>1022-36</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Proprotein convertases in health and disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Artenstein]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Opal]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med USA]]></source>
<year>2011</year>
<volume>365</volume>
<page-range>2507-18</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The PCSK9 decade Thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lambert]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sjouke]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Choque]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kastelein]]></surname>
<given-names><![CDATA[JJP]]></given-names>
</name>
<name>
<surname><![CDATA[Hovingh]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
</person-group>
<source><![CDATA[J Lipid Res USA]]></source>
<year>2012</year>
<volume>53</volume>
<page-range>2515-24</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sequence variations in PCSK9, low LDL, and protection against coronary heart disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Boerwinkle]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mosley]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Hobbs]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med USA]]></source>
<year>2006</year>
<volume>354</volume>
<page-range>1264-72</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[From the discovery of monoclonal antibodies to their therapeutic application: An historical reappraisal]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ribatti]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Immunol Lett Italia]]></source>
<year>2014</year>
<volume>161</volume>
<page-range>96-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Continuous cultures of fused cells secreting antibody of predefined specificity]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kôhler]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Milstein]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature]]></source>
<year>1975</year>
<volume>256</volume>
<page-range>495-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The history of monoclonal antibody development Progress, remaining challenges and future innovations]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[JKH]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Med Surg (Lond)]]></source>
<year>2014</year>
<volume>3</volume>
<page-range>113-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The safety of therapeutic monoclonal antibodies Implications for cardiovascular disease and targeting the PCSK9 pathway]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catapano]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Papadopoulos]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Atherosclerosis]]></source>
<year>2013</year>
<volume>228</volume>
<page-range>18-28</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A 52-week placebo-controlled trial of evolocumab in hyperlipidemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blom]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hala]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bolognese]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>370</volume>
<page-range>1809-19</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PCSK9 inhibition the way forward in the treatment of dyslipidemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stoekenbroek]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Kastelein]]></surname>
<given-names><![CDATA[JJP]]></given-names>
</name>
<name>
<surname><![CDATA[Huijgen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Med]]></source>
<year>2015</year>
<volume>13</volume>
<page-range>258</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Alirocumab in patients with heterozygous familial hyper-cholesterolaemia undergoing lipoprotein apheresis the ODYSSEY ESCAPE trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moriarty]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Parhofer]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Babirak]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Cornier]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J]]></source>
<year>2016</year>
<volume>37</volume>
<page-range>3588-95</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="">
<collab>Pfizer Inc.</collab>
<source><![CDATA[Pfizer]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A highly durable RNAi therapeutic inhibitor of PCSK9]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Borodovsky]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bettencourt]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>376</volume>
<page-range>41-51</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ference]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brook]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Catapano]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<page-range>2144-53</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Peptide-based anti-PCSK9 vaccines-an approach for long-term LDLc management]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galabova]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brunner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Winsauer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Juno]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wanko]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mairhofer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS ONE]]></source>
<year>2014</year>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hipercolesterolemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abifadel]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Atherosclerosis]]></source>
<year>2012</year>
<volume>223</volume>
<page-range>394-400</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Genetic basis of familial hypercholeste-rolemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Castro-Orós]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Appl Clin Genet]]></source>
<year>2010</year>
<volume>3</volume>
<page-range>53-64</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PCSK9 and LDLR degradation regulatory mechanisms in circulation and in cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lagace]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Lipidol]]></source>
<year>2014</year>
<volume>25</volume>
<page-range>387-93</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
